1 withdrawn. 1 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 1 | 1 | Withdrawn 1 |
Follow Xeroderma Pigmentosum: new trials by email Literature Review of Xeroderma Pigmentosum trials Research Report on Xeroderma Pigmentosum
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Testing the Combination of Two Immunotherapy Drugs (Nivolumab and Ipilimumab) in Children, Adolescent, and Young Adult Patients With Relapsed/Refractory Cancers That Have an Increased Number of Genetic Changes, The 3CI Study Biospecimen Collection, Ipilimumab, Nivolumab - Constitutional Mismatch Repair Deficiency Syndrome, Hematopoietic and Lymphoid Cell Neoplasm | Phase 1 | Withdrawn | National Cancer Institute (NCI) | 2021-05-11 | 2026-06-10 |
Central Nervous System Neoplasms (1) · Colorectal Neoplasms, Hereditary Nonpolyposis (1) · Hematologic Neoplasms (1) · Lymphoma (1) · Neuroblastoma (1) · Turcot syndrome (1)
Colonic Diseases (1) · Colorectal Neoplasms (1) · Congenital Abnormalities (1) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (1) · DNA Repair-Deficiency Disorders (1) · Digestive System Diseases (1) · Digestive System Neoplasms (1) · Gastrointestinal Diseases (1) · Gastrointestinal Neoplasms (1) · Genetic Diseases, Inborn (1) · Hematologic Diseases (1) · Hemic and Lymphatic Diseases (1) · Immune System Diseases (1) · Immunoproliferative Disorders (1) · Intestinal Diseases (1)
CTLA-4 Antigen (1) · Ipilimumab (1) · Nivolumab (1) · Specimen Handling (1)
National Cancer Institute (NCI) (1)
Canada (1) · United States (1)
P30CA015704 (1), UM1CA154967 (1)